Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Completed · Not applicable · Has a placebo group

Conditions studied: PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms

In brief

The purpose of this study is to evaluate the safety and efficacy of individualized, Biometrics-guided Magnetic e-Resonance Therapy (MeRT) treatment of Post-Traumatic Stress Disorder

Key facts

Study ID

NCT02990793

Run by

Wave Neuroscience

People needed

158

Starts

2022-04-04

Expected to finish

2025-11-04

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must meet all inclusion criteria to qualify for enrollment in the study:
• Willing and able to consent to participate in the study
• Age 18 - 65 years
• Diagnosis of PTSD according to DSM-V criteria via CAPS-5
• Onset of symptoms meeting the DSM-5 criteria for PTSD symptoms persisting for a minimum of 6 months prior to the Screening Visit
• Minimum PCL-5 score of 30

You may not qualify if…

• Participants will be excluded from study participation if one or more of the following exclusion criteria apply:
• Index trauma occurred before the age of 16 years
• History of open skull injury
• History of a neurological disorder including, but not limited to:
• Seizure disorder
• Any condition likely to be associated with increased intracranial pressure
• Space occupying brain lesion
• History of cerebrovascular accident
• History of cerebral aneurysm
• EEG abnormalities that indicate risk of seizure, i.e., abnormal focal or general slowing, or ictal spikes, during the EEG recording
• Inability to calculate the EEG intrinsic alpha frequency at Screening
• Participation in any interventional research protocol within 3 months prior to the Screening Visit
• History of any type of ECT, rTMS, or MeRT treatment
• Treated within 30 days of the Screening Visit with any antipsychotic medication
• Treated within 30 days of the Screening Visit with any benzodiazepine or anticonvulsant medications
• Current treatment with any restricted concomitant medication (i.e., NDRI, SSRI, SNRI, or QBDZ) that has not been stable for the preceding 60 days at the time of the Screening Visit
• Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within the head, excluding the mouth, or on the head, that cannot be safely removed
• Biomedical devices, including those not in or on the head, that are either implanted or not safe to remove, that may be affected by the magnetic field of the stimulator (e.g., cardiac pacemaker, cardioverter defibrillator (ICD), or medication dispensing device)
• Clinically significant medical illness or condition, including, but not limited to, any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunction, or chronic excessive alcohol consumption, that in the Investigator's judgment might pose a potential safety risk to the participant or limit the interpretation of trial results
• Pregnant, or female unwilling to use effective birth control during the course of the trial
• Plan to move away from the area, or knowledge that there will be an absence from the area, within 80 days following the Screening Visit (inclusive)
• Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures, or any condition, including inability to communicate in English, which in the judgment of the Investigator might prevent the participant from completing the study, render study results uninterpretable, or represent an unacceptable safety risk to the participant or study personnel that is not otherwise listed in exclusion criteria.
• Clinically significant psychopathology, including, but not limited to, schizophrenia or bipolar disorder, or other psychiatric disorder that in the Investigator's judgment might pose a potential safety risk to the participant, or limit the interpretation of trial results
• An elevated risk of suicide or violence to others
• Current psychotherapeutic treatment, expected to continue throughout the trial, that was begun in the preceding 60 days at the time of the Screening Visit

Where it is running

• BrainHealth Solutions — Costa Mesa, California, United States
• VA Long Beach Healthcare System — Long Beach, California, United States
• SoCal Neuroscience Research Unit — San Diego, California, United States
• UNC Rex Hospital — Raleigh, North Carolina, United States
• Columbus Brain Research Center — Columbus, Ohio, United States
• Center for Interventional Pain and Spine — Bryn Mawr, Pennsylvania, United States
• Texas A&M Research Center — Plano, Texas, United States
• Seattle Neuropsychiatric Treatment Center (Seattle NTC) — Bellevue, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.